Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis

What Was Tested

Researchers studied Tirzepatide in the context of atherosclerosis, cardiovascular disease & high blood pressure in this randomized controlled trial publication.

To assess the effect of tirzepatide on long-term risk of atherosclerotic cardiovascular disease (ASCVD) among people with obesity or overweight without diabetes from SURMOUNT-1.

Who Took Part

By PubMed's age tags, the people studied were adults.

The predicted 10-year ASCVD risk scores were calculated (American College of Cardiology/American Heart Association risk engine) at baseline, week 24, and week 72 in SURMOUNT-1 participants without a history of ASCVD.

Analyses were also conducted in participants with intermediate to high risk at baseline.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some participants received a placebo instead of Tirzepatide, giving a reference point.

Changes from baseline in cardiometabolic variables were assessed.

Percent change in risk scores from baseline to weeks 24 and 72 was compared between tirzepatide and placebo using mixed model for repeated measures analysis.

What Was Measured

PubMed files the paper under topics including Atherosclerosis, Cardiometabolic Risk Factors, Cardiovascular Diseases, Diabetes Mellitus, Diabetes Mellitus, Type 2, Hypoglycemic Agents and Obesity.

The authors tagged it with the keywords ASCVD and tirzepatide.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Tirzepatide in people with atherosclerosis, cardiovascular disease & high blood pressure.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Tirzepatide compound page, Atherosclerosis, cardiovascular disease & high blood pressure research.